Opiant Pharmaceuticals, Inc. (OPNT) Downgraded to “Buy” at ValuEngine

ValuEngine lowered shares of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) from a strong-buy rating to a buy rating in a research report sent to investors on Friday.

Separately, TheStreet raised shares of Opiant Pharmaceuticals from a c+ rating to a b rating in a report on Monday, October 16th.

Opiant Pharmaceuticals (NASDAQ OPNT) traded down 8.87% during trading on Friday, hitting $36.59. The stock had a trading volume of 291,982 shares. The firm has a market capitalization of $74.53 million, a PE ratio of 12.45 and a beta of -0.97. The firm has a 50 day moving average price of $35.94 and a 200-day moving average price of $17.87. Opiant Pharmaceuticals has a 1-year low of $5.00 and a 1-year high of $51.90.

Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its quarterly earnings results on Friday, October 13th. The technology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.70. Opiant Pharmaceuticals had a net margin of 35.68% and a return on equity of 278.86%. The company had revenue of $3.77 million for the quarter. On average, equities research analysts expect that Opiant Pharmaceuticals will post $0.50 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/28/opiant-pharmaceuticals-inc-opnt-downgraded-to-buy-at-valuengine.html.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply